Evidence map›Paper›PMID 24982872›Full record

ArticleBioMed research international2014

Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites.

Tomer Feigenberg, Blaise Clarke, Carl Virtanen, Anna Plotkin, Michelle Letarte, Barry Rosen, Marcus Q Bernardini, Alexandra Kollara, Theodore J Brown, K Joan Murphy

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 50 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Advances in the treatment of malignant ascites in China.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Tomer FeigenbergDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Department of Obstetrics and Gynaecology, Trillium Health Partners, 2200 Eglinton Avenue West, Mississauga, ON, Canada L5M 2N1.ORCID 0000-0003-3773-0018
Blaise ClarkeDepartment of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Department of Laboratory Medicine and Pathology, University Health Network, Toronto, ON, Canada M5T 2M9.
Carl VirtanenPrincess Margaret Genomics Centre, University Health Network, Toronto, ON, Canada M5G 1L7.
Anna PlotkinDepartment of Laboratory Medicine and Pathology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Department of Laboratory Medicine and Pathology, Trillium Health Partners, Mississauga, ON, Canada L5M 2N1.
Michelle LetarteHospital for Sick Children and Department of Immunology, University of Toronto, Toronto, ON, Canada M5G 1X8.ORCID 0000-0002-5901-7582
Barry RosenDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2M9.
Marcus Q BernardiniDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2M9.
Alexandra KollaraLunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada M5T 3L9.ORCID 0000-0002-6786-9582
Theodore J BrownLunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, Toronto, ON, Canada M5T 3L9.
K Joan MurphyDivision of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada M5G 2M9 ; Division of Gynaecologic Oncology, Department of Obstetrics and Gynaecology, Princess Margaret Cancer Centre, Toronto, ON, Canada M5G 2M9.
University of Toronto · CALunenfeld-Tanenbaum Research Institute · CAUniversity Health Network · CA

Funding

Canadian Institutes of Health Research MOP106679
6 · The paper itself

Abstract

Epithelial ovarian cancer consists of multiple histotypes differing in etiology and clinical course. The most prevalent histotype is high-grade serous ovarian cancer (HGSOC), which often presents at an advanced stage frequently accompanied with high-volume ascites. While some studies suggest that ascites is associated with poor clinical outcome, most reports have not differentiated between histological subtypes or tumor grade. We compared genome-wide gene expression profiles from a discovery cohort of ten patients diagnosed with stages III-IV HGSOC with high-volume ascites and nine patients with low-volume ascites. An upregulation of immune response genes was detected in tumors from patients presenting with low-volume ascites relative to those with high-volume ascites. Immunohistochemical studies performed on tissue microarrays confirmed higher expression of proteins encoded by immune response genes and increased tumorinfiltrating cells in tumors associated with low-volume ascites. Comparison of 149 advanced-stage HGSOC cases with differential ascites volume at time of primary surgery indicated low-volume ascites correlated with better surgical outcome and longer overall survival. These findings suggest that advanced stage HGSOC presenting with low-volume ascites reflects a unique subgroup of HGSOC, which is associated with upregulation of immune related genes, more abundant tumor infiltrating cells and better clinical outcomes.

Indexed as

Gene Expression ProfilingAdultAgedAged, 80 and overAscitesCarcinoma, Ovarian EpithelialCystadenocarcinoma, SerousFemaleGene Expression Regulation, NeoplasticGene OntologyHumansImmunityMiddle AgedNeoplasm ProteinsNeoplasms, Glandular and EpithelialOvarian NeoplasmsNeoplasm Proteins

Identifiers

PMID24982872
PMCPMC4055662
OpenAlexW2097783842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.